News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
284,926 Results
Type
Article (15081)
Company Profile (296)
Press Release (269541)
Multimedia
Podcasts (89)
Webinars (12)
Section
Business (79911)
Career Advice (164)
Deals (13364)
Drug Delivery (42)
Drug Development (50812)
Employer Resources (31)
FDA (5875)
Job Trends (5185)
News (145309)
Policy (10090)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (931)
Accelerated approval (24)
Adcomms (14)
Allergies (95)
Alliances (21764)
ALS (148)
Alzheimer's disease (1094)
Antibody-drug conjugate (ADC) (303)
Approvals (6104)
Artificial intelligence (316)
Autoimmune disease (178)
Automation (10)
Bankruptcy (105)
Best Places to Work (4565)
BIOSECURE Act (6)
Biosimilars (111)
Biotechnology (229)
Bladder cancer (114)
Brain cancer (53)
Breast cancer (375)
Cancer (3532)
Cardiovascular disease (272)
Career advice (149)
Career pathing (8)
CAR-T (238)
CDC (6)
Cell therapy (623)
Cervical cancer (20)
Clinical research (44277)
Collaboration (1319)
Company closure (2)
Compensation (675)
Complete response letters (51)
COVID-19 (1115)
CRISPR (96)
C-suite (659)
Cystic fibrosis (116)
Data (4933)
Denatured (18)
Depression (105)
Dermatology (37)
Diabetes (277)
Diagnostics (1407)
Digital health (15)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (234)
Drug pricing (51)
Drug shortages (3)
Duchenne muscular dystrophy (254)
Earnings (32204)
Editorial (28)
Employer branding (4)
Employer resources (29)
Events (52414)
Executive appointments (658)
FDA (7843)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (13)
Frontotemporal dementia (29)
Funding (1104)
Gene editing (200)
Generative AI (29)
Gene therapy (544)
GLP-1 (540)
Government (1170)
Grass and pollen (3)
Guidances (171)
Healthcare (6647)
HIV (23)
Huntington's disease (47)
IgA nephropathy (78)
Immunology and inflammation (216)
Immuno-oncology (64)
Indications (106)
Infectious disease (1249)
Inflammatory bowel disease (166)
Inflation Reduction Act (10)
Influenza (50)
Intellectual property (186)
Interviews (18)
IPO (7351)
IRA (13)
Job creations (868)
Job search strategy (130)
JPM (41)
Kidney cancer (9)
Labor market (25)
Layoffs (247)
Leadership (10)
Legal (1410)
Liver cancer (43)
Longevity (19)
Lung cancer (470)
Lymphoma (272)
Machine learning (29)
Management (7)
Manufacturing (441)
MASH (143)
Medical device (2699)
Medtech (2709)
Mergers & acquisitions (6690)
Metabolic disorders (816)
mRNA (128)
Multiple sclerosis (114)
NASH (14)
Neurodegenerative disease (284)
Neuropsychiatric disorders (76)
Neuroscience (2142)
Neurotech (1)
NextGen: Class of 2026 (2040)
Non-profit (872)
Now hiring (37)
Obesity (374)
Opinion (133)
Ovarian cancer (149)
Pain (118)
Pancreatic cancer (180)
Parkinson's disease (273)
Partnered (12)
Patents (350)
Patient recruitment (427)
Peanut (46)
People (26933)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15697)
Phase 2 (20600)
Phase 3 (12975)
Pipeline (4612)
Policy (98)
Postmarket research (854)
Preclinical (6623)
Press Release (30)
Prostate cancer (170)
Psychedelics (51)
Radiopharmaceuticals (257)
Rare diseases (784)
Real estate (1449)
Recruiting (12)
Regulatory (10232)
Reports (20)
Research institute (978)
Resumes & cover letters (20)
Rett syndrome (30)
RNA editing (22)
RSV (22)
Schizophrenia (136)
Series A (211)
Series B (151)
Service/supplier (1)
Sickle cell disease (85)
Special edition (19)
Spinal muscular atrophy (124)
Sponsored (16)
Startups (2017)
State (1)
Stomach cancer (5)
Supply chain (36)
Tariffs (18)
The Weekly (69)
Vaccines (371)
Venture capital (77)
Weight loss (199)
Women's health (37)
Worklife (2)
Date
Today (11)
Last 7 days (269)
Last 30 days (1491)
Last 365 days (17759)
2026 (4878)
2025 (18102)
2024 (20549)
2023 (22422)
2022 (26830)
2021 (27813)
2020 (23363)
2019 (16240)
2018 (11745)
2017 (13766)
2016 (11857)
2015 (14355)
2014 (10398)
2013 (7488)
2012 (7534)
2011 (7615)
2010 (7430)
Location
Africa (154)
Alabama (71)
Alaska (2)
Arizona (77)
Arkansas (6)
Asia (18458)
Australia (3155)
California (7764)
Canada (2019)
China (883)
Colorado (286)
Connecticut (284)
Delaware (262)
Europe (39640)
Florida (1002)
Georgia (228)
Hawaii (2)
Idaho (17)
Illinois (445)
India (40)
Indiana (181)
Iowa (8)
Japan (266)
Kansas (82)
Kentucky (10)
Louisiana (12)
Maine (11)
Maryland (809)
Massachusetts (6150)
Michigan (119)
Minnesota (277)
Mississippi (3)
Missouri (34)
Montana (17)
Nebraska (6)
Nevada (41)
New Hampshire (21)
New Jersey (1807)
New Mexico (13)
New York (1941)
North Carolina (904)
North Dakota (6)
Northern California (3870)
Ohio (196)
Oklahoma (11)
Oregon (23)
Pennsylvania (1430)
Puerto Rico (10)
Rhode Island (27)
South America (216)
South Carolina (11)
Southern California (3104)
Tennessee (47)
Texas (1033)
United States (25716)
Utah (107)
Virginia (159)
Washington D.C. (37)
Washington State (637)
West Virginia (1)
Wisconsin (50)
284,926 Results for "repare therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.
January 29, 2026
·
6 min read
Press Releases
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
January 19, 2026
·
7 min read
Press Releases
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
November 17, 2025
·
17 min read
Press Releases
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
November 21, 2025
·
6 min read
Press Releases
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
December 25, 2025
·
8 min read
Layoffs
Repare Therapeutics to Cut Staff Again, This Time by 75%
The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.
February 25, 2025
·
2 min read
·
Angela Gabriel
Press Releases
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
July 16, 2025
·
7 min read
Press Releases
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 8, 2025
·
11 min read
Press Releases
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
·
2 min read
Press Releases
Repare Therapeutics Announces Leadership Transitions
April 1, 2025
·
6 min read
1 of 28,493
Next
